Adagrasib significantly improves progression-free survival (PFS) compared to docetaxel in KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients previously treated with chemotherapy and immunotherapy.
Olomorasib combined with pembrolizumab demonstrated a 77% overall response rate in first-line NSCLC patients with KRAS G12C mutations, regardless of PD-L1 expression.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.